Calidi Biotherapeutics Inc Stock Price, News & Analysis

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, has announced the pricing of a $6 million underwritten public offering. The offering consists of 1,472,764 common stock units at $2.00 per unit and 1,528,000 pre-funded warrant units at $1.999 per unit.

Each common stock unit includes one share and one Series I warrant, while pre-funded warrant units include one pre-funded warrant and one Series I warrant. The Series I warrants have a $2.00 exercise price and a 5-year term. Ladenburg Thalmann & Co. Inc. is acting as the sole book-running manager, with Laidlaw & Company as co-manager. The offering is expected to close around August 21, 2025.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company, reported its Q2 2025 financial results and operational highlights. The company presented promising preclinical data for CLD-401 at ASCO, demonstrating enhanced biological efficacy in delivering IL-15 superagonist to metastatic tumors. Additionally, CLD-201 received FDA Fast Track Designation for soft tissue sarcoma treatment.

Financially, Calidi raised $4.6 million through a warrant inducement offering, bringing total 2025 gross proceeds to $15.7 million. The company reported a net loss of $5.7 million ($1.99 per share) in Q2 2025, compared to $7.4 million in Q2 2024. Cash position stood at $5.3 million as of June 30, 2025.

Calidi Biotherapeutics (NYSE American: CLDI) has received Fast Track designation from the FDA for CLD-201 (SuperNova), its allogeneic adipose stem-cell loaded oncolytic virus therapy for soft tissue sarcoma treatment.

The Fast Track status enables more frequent FDA interactions and potential eligibility for priority review and accelerated approval. This designation is granted to products addressing serious conditions with unmet medical needs.

Following the April 2025 FDA IND clearance, Calidi plans to conduct a Phase 1 first-in-human trial evaluating CLD-201's safety, tolerability, and efficacy in treating sarcoma, triple-negative breast cancer, and head and neck squamous cell carcinoma.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company, has announced a 1-for-12 reverse stock split effective August 5, 2025. The reverse split was approved by stockholders on July 9, 2025, and by the Board of Directors on July 11, 2025.

Under the split, every 12 pre-split shares will be consolidated into one share, with fractional shares rounded up to the nearest whole share at the participant level. The company will maintain its "CLDI" trading symbol with a new CUSIP number 320703 408. Proportionate adjustments will be made to outstanding options, warrants, and convertible securities.

The split will not affect the par value of common stock, authorized but unissued shares, or authorized preferred stock. Equiniti Trust Company has been appointed as the exchange agent to facilitate the process.

Calidi Biotherapeutics (NYSE American: CLDI) will host an investor webinar on July 24, 2025, at 4:15 p.m. ET featuring CEO Eric Poma. The presentation will highlight their RedTail™ platform, an engineered viral therapy system designed to deliver genetic medicines to metastatic tumors.

The company's lead candidate, CLD-401, has shown promising preclinical results at AACR and ASCO, demonstrating tumor elimination and immune memory development. The targeted oncology market is projected to reach $560 billion by 2033. Calidi is progressing toward IND filing while seeking strategic pharma partnerships for global commercialization.

Calidi Biotherapeutics (NYSE American: CLDI) is developing a next-generation platform for cancer treatment using engineered viruses to deliver genetic medicines directly to tumors. The company's innovative approach targets both primary and metastatic tumors, addressing a critical healthcare need as cancer diagnoses are projected to reach 35 million annually by 2050.

While initially focused on oncology, Calidi is also exploring applications in autoimmune disorders. This development comes as global cancer cases reach 20 million diagnoses and 10 million deaths annually, highlighting the urgent need for more effective treatment options.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company, has secured approximately $4.6 million in gross proceeds through the exercise of multiple series of warrants. The agreement involves the immediate exercise of Series A, B-1, C-1, D, E, and F warrants for 6,595,000 shares at a reduced price of $0.70 per share.

In exchange for the immediate cash exercise, Calidi will issue new unregistered warrants to purchase up to 6,595,000 shares at $0.70 per share, exercisable after six months with a 5.5-year term. The proceeds will support clinical and pre-clinical programs, operating expenses, and working capital. Ladenburg Thalmann & Co. is serving as the exclusive placement agent.

Calidi Biotherapeutics (NYSE American: CLDI) is developing a precision genetic medicine platform for cancer treatment. The company's innovative approach focuses on using engineered viruses to deliver genetic medicines that can target both primary tumors and metastatic sites.

The development comes amid concerning cancer statistics, with 20 million annual cancer diagnoses globally and projections showing this number could reach 35 million by 2050. Currently, cancer claims nearly 10 million lives annually worldwide, highlighting the urgent need for more effective treatment options.

Calidi Biotherapeutics (NYSE American: CLDI) issued a shareholder letter highlighting significant company developments under new CEO Eric Poma. The company's primary focus is advancing their RedTail platform, a systemic virotherapy platform for delivering genetic medicines to metastatic cancer sites.

Key developments include the appointment of Dr. Guy Travis Clifton as CMO, positive preclinical data presentations at AACR and ASCO meetings, and plans for an IND filing by end of 2026 for CLD-401, their lead RedTail candidate. The company also opened an IND for SuperNova virotherapy (CLD-201) with phase I trials expected to start by end of 2025.

Financially, Calidi reported $10.6 million in cash at Q1 2025 end, with reduced costs and lower burn rate. The company has retired most of its debt and is exploring partnership opportunities with leading biopharmaceutical companies.